Cargando…

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer

Erlotinib hydrochloride (Tarceva(®)) is a member of a class of small molecule inhibitors that targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), with anti-tumor activity in preclinical models. Erlotinib represents a new-generation of agents known as “targeted therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Reguart, Noemí, Cardona, Andrés Felipe, Rosell, Rafael
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004579/
https://www.ncbi.nlm.nih.gov/pubmed/21188105
_version_ 1782194000710598656
author Reguart, Noemí
Cardona, Andrés Felipe
Rosell, Rafael
author_facet Reguart, Noemí
Cardona, Andrés Felipe
Rosell, Rafael
author_sort Reguart, Noemí
collection PubMed
description Erlotinib hydrochloride (Tarceva(®)) is a member of a class of small molecule inhibitors that targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), with anti-tumor activity in preclinical models. Erlotinib represents a new-generation of agents known as “targeted therapies” designed to act upon cancer cells by interfering with aberrant specific activated pathways needed for tumor growth, angiogenesis and cell survival. Since its approval in November 2004 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior chemotherapy regimen and with a view to improving patients’ outcomes and prevent symptoms, the scientific community has evaluated the potential role of erlotinib in other scenarios such as in maintenance therapy and, in first-line setting for a selected population based on biological markers of response such as mutations of the EGFR. The convenient once-a-day pill administration and the good toxicity profile of erlotinib make it a reasonable candidate for testing in this context. This report provides a review of the role of erlotinib therapy in advanced NSCLC. It summarizes current data and perspectives of erlotinib in upfront treatment and maintenance for advanced NSCLC as well as looking at candidate biomarkers of response to these new targeted-agents.
format Text
id pubmed-3004579
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-30045792010-12-23 Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer Reguart, Noemí Cardona, Andrés Felipe Rosell, Rafael Cancer Manag Res Review Erlotinib hydrochloride (Tarceva(®)) is a member of a class of small molecule inhibitors that targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), with anti-tumor activity in preclinical models. Erlotinib represents a new-generation of agents known as “targeted therapies” designed to act upon cancer cells by interfering with aberrant specific activated pathways needed for tumor growth, angiogenesis and cell survival. Since its approval in November 2004 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior chemotherapy regimen and with a view to improving patients’ outcomes and prevent symptoms, the scientific community has evaluated the potential role of erlotinib in other scenarios such as in maintenance therapy and, in first-line setting for a selected population based on biological markers of response such as mutations of the EGFR. The convenient once-a-day pill administration and the good toxicity profile of erlotinib make it a reasonable candidate for testing in this context. This report provides a review of the role of erlotinib therapy in advanced NSCLC. It summarizes current data and perspectives of erlotinib in upfront treatment and maintenance for advanced NSCLC as well as looking at candidate biomarkers of response to these new targeted-agents. Dove Medical Press 2010-06-01 /pmc/articles/PMC3004579/ /pubmed/21188105 Text en © 2010 Reguart et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Reguart, Noemí
Cardona, Andrés Felipe
Rosell, Rafael
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
title Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
title_full Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
title_fullStr Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
title_full_unstemmed Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
title_short Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
title_sort role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004579/
https://www.ncbi.nlm.nih.gov/pubmed/21188105
work_keys_str_mv AT reguartnoemi roleoferlotinibinfirstlineandmaintenancetreatmentofadvancednonsmallcelllungcancer
AT cardonaandresfelipe roleoferlotinibinfirstlineandmaintenancetreatmentofadvancednonsmallcelllungcancer
AT rosellrafael roleoferlotinibinfirstlineandmaintenancetreatmentofadvancednonsmallcelllungcancer